- Details
- Wassim Abida, MD, PhD, and colleagues presented an abstract titled, "Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC)" at the 2021 ASCO GU Cancers Symposium. Dr. Wasim Abida joins Charles Ryan, MD highlighting the data that was presented, providing further insight...
|
- Details
- The University of Minnesota has recently launched the CASPAR randomized Phase III clinical trial of enzalutamide and rucaparib versus enzalutamide and placebo in first-line metastatic castrate-resistant prostate cancer (CRPC). Alicia Morgans is joined by Arpit Rao from the Univesity of Minnesota to discuss the launch and the initial success of this new trial. Biographies: Arpit Rao, MD, MBBS, Assi...
|
- Details
- Metastatic castration-resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, an androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in the treatment of advanced pr...
|
- Details
- The field of advanced prostate cancer has rapidly progressed. Prior to the publication of TAX-327, in 2004 there were no proven life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time there have been many new agents that have proven survival benefits including taxane-based chemotherapy, agents targeting the androgen axis, and bone-target...
|
- Details
- Arpit Rao joins Alicia Morgans to discuss the Phase I RAMP trial, looking at the combination of enzalutamide and rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Preclinical studies have demonstrated potential synthetic lethality between androgen receptor signaling inhibition and PARP inhibition, which led to the investigation of these two drugs in combination. The RAMP study...
|
- Details
- In this Journal Club video presentation, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD describe a Clinical Genitourinary Cancer publication Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. The primary objective of this analysis is to describe real-world treatment patterns, includ...
|
- Details
- Treatment options in metastatic castration-resistant prostate cancer (mCRPC) who have soft-tissue progression after second-generation anti-androgen therapies are limited. Single-agent studies of cabozantinib, a tyrosine kinase inhibitor (TKI) that regulates cell growth, angiogenesis, and immune cell regulation, and the anti-PD-L1 antibody atezolizumab each showed limited efficacy as monotherapy. (...
|
- Details
- Tanya Dorff joins Alicia Morgans discussing recent updates to the NCCN guidelines for systemic therapies in the treatment of M1 prostate cancer. The CARD trial was a multicenter, randomized, open-label study that enrolled men with metastatic castration-resistant prostate cancer (mCRPC) between 2015 and 2018. Patients were eligible if they had evidence of symptomatic progressive disease within 12 m...
|
- Details
- Rucaparib was evaluated as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA gene alteration who had received prior taxane and androgen receptor–directed therapy. In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the clinical rationale which led to the exploration of PARP inhibitors in men with advanced prostate can...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Ben Tran, MBBS, FRACP, highlights the interim results from a phase 1 study of AMG160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) presented at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. Biographies: Ben Tran, MBB...
|
